Our COO/CSO, Karen Wen was invited at Taiwan HSCT & Cell Therapy Congress 2024 in NTUH, Taiwan (July 13, 2024)

2024-07-16

Taiwan FDA clears GenomeFrontier’s IND application for GF-CART01, a CD20/CD19 dual targeting CAR T cell therapy for hematological B cell malignancies!

2025-02-11

留言

Your email address will not be published. Required fields are marked *